Furthermore, since TAMs may contribute to tumour resistance to current chemotherapies56, targeting TAMs by blocking their key paracrine mediator PTN may synergize with conventional anti-GBM therapies to improve patient survival. The gene discussed is PTN; the disease is glioblastoma.